North America holds 41.86% of global monogenetic disorders testing revenue in 2025, or USD 272.1 million, making it the largest region in the market by a wide margin. Contrive Datum Insights has published "Monogenetic Disorders Testing Market Size, Share & Industry Analysis" with a regional forecast for 2026-2034, covering five axes: test type, disease type, end-user, technology, and product and service.
The Market and Its Regions
The study sizes the global market at USD 650 million in 2025 and projects growth from USD 715 million in 2026 to USD 1692.1 million by 2034, a compound annual growth rate of 11.37%. The market covers laboratory assays that detect single-gene mutations behind inherited conditions such as cystic fibrosis, sickle cell anemia and Tay-Sachs disorder. Samples of blood, saliva or amniotic fluid are run on PCR, next-generation sequencing, Sanger sequencing, microarray or FISH platforms.
North America is projected to reach USD 643 million by 2034. Asia Pacific is the closest follower and gains ground: its share rises from 22.5% in 2025 to 27% in 2034, as revenue grows from USD 146.3 million to USD 456.9 million. Middle East and Africa stays the smallest region throughout, at 3.86% of 2025 revenue and 4.5% by 2034. At country level, the United States is the largest single market, at USD 239.4 million in 2025, or 36.83% of global revenue.
By test type, Diagnostic Testing is the biggest line, with 31.98% of 2025 revenue (USD 207.9 million). Prenatal Testing grows fastest at 13.93%, lifting its share from 24% to 29.58% and its value from USD 156 million to USD 500.5 million. The other axes follow a similar split between the largest line and the fastest:
- Disease type: Thalassaemia leads in 2025 with 18% of revenue (USD 117 million); Familial Hypercholesterolemia grows fastest at 14.01%.
- End-user: Hospitals lead with 52% (USD 338 million); Specialized Clinics grow fastest at 12.6%.
- Technology: Next-Generation Sequencing (NGS) leads with 34% (USD 221 million).
- Product and service: Reagents & Consumables lead with 58% (USD 377 million); Software & Services grow fastest at 14.83%.
What Could Loosen North America's Hold
The study names rising global prevalence of inherited disorders and expanding newborn screening mandates as the largest single contributor to growth, and it rates the impact high. A leading region benefits from that demand, but it does not own it. Asia Pacific's climb to 27% of revenue shows where new volume is landing.
The scenarios show how far the outcome can swing. In the bull case, sequencing costs fall faster than expected and newborn screening mandates reach more jurisdictions sooner, pulling next-generation sequencing panels forward and taking 2034 revenue to USD 1874.9 million. In the bear case, reimbursement for genetic testing stalls in emerging markets and the shortage of trained genetic counselors lasts longer than assumed. Fewer eligible patients become tested patients, and 2034 revenue stays at USD 1539.8 million.
A slower market would test the largest region too. Diagnostic Testing, the biggest line at 31.98% of 2025 revenue, grows at 10.32%, below the market's 11.37%, so the faster prenatal and sequencing-led lines carry more of the growth each year.
The report includes revenue and a growth rate for every line in every year from 2020 to 2034, bear, base and bull scenarios, country-level breakdowns for all five regions, the competitive landscape, and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.